Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Recommendation of “Hold” from Brokerages

Prestige Consumer Healthcare Inc. (NYSE:PBH) has been assigned an average recommendation of “Hold” from the seven research firms that are covering the firm, Marketbeat reports. Four analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $76.50.

Several research analysts recently issued reports on the company. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Jefferies Financial Group lowered their target price on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a report on Friday, January 30th.

Prestige Consumer Healthcare Price Performance

Shares of NYSE PBH opened at $59.22 on Friday. The stock has a market cap of $2.80 billion, a price-to-earnings ratio of 15.67, a PEG ratio of 1.86 and a beta of 0.41. Prestige Consumer Healthcare has a 52 week low of $57.25 and a 52 week high of $89.37. The company’s 50-day moving average price is $65.43 and its 200 day moving average price is $63.12. The company has a current ratio of 3.11, a quick ratio of 1.93 and a debt-to-equity ratio of 0.58.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). The business had revenue of $283.44 million for the quarter, compared to analyst estimates of $286.93 million. Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The business’s revenue was down 2.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.22 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. As a group, research analysts forecast that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Jeffrey Zerillo sold 1,000 shares of the stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total transaction of $65,930.00. Following the sale, the vice president owned 41,048 shares of the company’s stock, valued at $2,706,294.64. This trade represents a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. UMB Bank n.a. boosted its stake in shares of Prestige Consumer Healthcare by 110.1% during the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after purchasing an additional 219 shares during the last quarter. Bayforest Capital Ltd acquired a new position in shares of Prestige Consumer Healthcare in the fourth quarter valued at approximately $29,000. First Horizon Corp acquired a new position in shares of Prestige Consumer Healthcare in the third quarter valued at approximately $32,000. Barrow Hanley Mewhinney & Strauss LLC lifted its stake in shares of Prestige Consumer Healthcare by 106.8% during the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock valued at $34,000 after buying an additional 283 shares during the period. Finally, Torren Management LLC purchased a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at approximately $35,000. Institutional investors and hedge funds own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).